Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DIAPH3 antisense RNA 2 (DIAPH3-AS2) is a long non-coding RNA (lncRNA) transcribed antisense to the DIAPH3 (diaphanous-related formin 3) gene[1][2]. While the sense gene DIAPH3 encodes a protein involved in actin dynamics, cell movement, and has been implicated in cancer and auditory neuropathy, the specific functions and mechanisms of DIAPH3-AS2 remain under study[2]. The transcript is one of several DIAPH3 antisense RNAs with possible regulatory roles in gene expression, potentially through interfering with or modulating DIAPH3 expression[2]. There is emerging but not definitive evidence of a role in cancer, especially triple-negative breast cancer, but its exact biological and pathological significance requires further investigation[2]. At present, DIAPH3-AS2 is not a recognized pharmacological target, nor is it linked to any approved or investigational drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DIAPH3 antisense RNA 2 (DIAPH3-AS2).